Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

1.

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.

Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ.

Expert Rev Anticancer Ther. 2014 Aug;14(8):887-900. doi: 10.1586/14737140.2014.915194. Epub 2014 Jun 23.

PMID:
24953238
[PubMed - in process]
2.

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.

Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group.

Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089.

PMID:
24557434
[PubMed - in process]
3.

Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor.

Uriol E, Sierra M, Comendador MA, Fra J, Martínez-Camblor P, Lacave AJ, Sierra LM.

Mutagenesis. 2013 Jan;28(1):39-48. doi: 10.1093/mutage/ges050. Epub 2012 Sep 17.

PMID:
22987025
[PubMed - indexed for MEDLINE]
Free Article
4.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

PMID:
22018631
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

PMID:
21892704
[PubMed - indexed for MEDLINE]
6.

Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.

Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ.

Int J Gynecol Cancer. 2011 Apr;21(3):478-85. doi: 10.1097/IGC.0b013e31820d738c.

PMID:
21436695
[PubMed - indexed for MEDLINE]
7.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group.

N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.

PMID:
20818904
[PubMed - indexed for MEDLINE]
Free Article
8.

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ.

Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0.

PMID:
20709657
[PubMed - indexed for MEDLINE]
9.

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ.

Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13.

PMID:
20464446
[PubMed - indexed for MEDLINE]
10.

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Viéitez JM, Valladares M, Peláez I, de Sande González L, García-Foncillas J, García-López JL, García-Girón C, Reboredo M, Bovio H, Lacave AJ.

Invest New Drugs. 2011 Oct;29(5):1038-44. doi: 10.1007/s10637-010-9400-z. Epub 2010 Mar 6.

PMID:
20204674
[PubMed - indexed for MEDLINE]
11.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

PMID:
19692688
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

PMID:
19528136
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

PMID:
19474112
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

PMID:
18981464
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy.

Fonseca PJ, Esteban E, de Vicente P, Luque M, Llorente B, Capelán M, Berros JP, Crespo G, Lacave AJ.

Clin Transl Oncol. 2008 Jul;10(7):426-32.

PMID:
18628072
[PubMed - indexed for MEDLINE]
16.

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.

Esteban E, de Sande JL, Villanueva N, Corral N, Muñiz I, Vieitez JM, Fra J, Fernández Y, Estrada E, Fernandez JL, Luque M, Jimenez P, Mareque B, Capellan M, Buesa JM, Lacave AJ.

Lung Cancer. 2007 Feb;55(2):173-80. Epub 2006 Oct 27.

PMID:
17070962
[PubMed - indexed for MEDLINE]
17.

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG.

J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11.

PMID:
16966687
[PubMed - indexed for MEDLINE]
Free Article
18.

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.

Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON).

Invest New Drugs. 2006 May;24(3):241-8.

PMID:
16096704
[PubMed - indexed for MEDLINE]
19.

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.

Esteban-Gonzalez E, Fernández Y, Villanueva N, Fra J, Muñiz I, Palacio I, Vieitez JM, Uña E, Mareque B, Lacave AJ.

Invest New Drugs. 2005 Dec;23(6):597-601.

PMID:
16034519
[PubMed - indexed for MEDLINE]
20.

Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease.

Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C.

Melanoma Res. 2005 Feb;15(1):53-60.

PMID:
15714121
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk